• Sign In
  • FAQ
  • Create an Account
  • 866-930-6790
Currency
USD
Toggle Nav
My Cart
Search
Menu
Account
Settings
Currency
USD

VEGFR

Items 1-50 of 124

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. A10001
    Sorafenib Tosylate (Nexavar)

    Raf inhibitor

    Sorafenib Tosylate (Nexavar) is a novel, small molecular inhibitor of several tyrosine protein kinases (VEGFR and PDGFR) and RAF/MEK/ERK cascade inhibitor with an IC50 of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF.
    Quick View
  2. A10025
    Linifanib (ABT-869)

    VEGFR/PDGFR inhibitor

    Linifanib (ABT-869) is a structurally novel, potent inhibitor of RTK, VEGF and PDGF with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGFR-β, KDR, and CSF-1R, respectively.
    Quick View
  3. A10043
    AEE788

    EGFR inhibitor

    AEE788 is an orally bioavailable multiple-receptor tyrosine kinase inhibitor that inhibits phosphorylation of the tyrosine kinases of EGFR, HER2 and VEGF2.
    Quick View
  4. A10101
    Tivozanib (AV-951)

    VEGFR Inhibitor

    Tivozanib (AV-951) is an oral VEGF receptor tyrosine kinase inhibitor that is designed to inhibit all three VEGF receptors.
    Quick View
  5. A10103
    Axitinib

    VEGFR inhibitor

    Axitinib is a small molecule tyrosine kinase inhibitor,which inhibits multiple targets, including VEGFR-1, VEGFR-2, VEGFR-3, platelet derived growth factor receptor (PDGFR), and cKIT (CD117).
    Quick View
  6. A10137
    Bibf1120 (Nintedanib)

    VEGFR inhibitor

    BIBF1120 (Vargatef) is a novel triple angiokinase inhibitor that inhibits three growth factor receptors simultaneously: VEGFR, PDGF and FGFR.
    Quick View
  7. A10154
    BMS-794833

    c-Met inhibitor

    BMS-794833 is a potent ATP competitive inhibitor to Met and VEGFR-2 with IC50 of 1.7 and 15 nmol.
    Quick View
  8. A10162
    Brivanib alaninate (BMS-582664)

    VEGFR inhibitor

    Brivanib alaninate (BMS-582664) is a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling.
    Quick View
  9. A10185
    Cediranib (AZD2171)

    VEGFR inhibitor

    Cediranib (AZD2171) is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.
    Quick View
  10. A10198
    Dovitinib Dilactic acid (TKI258 Dilactic acid)

    RTK inhibitor

    Dovitinib is a small-molecule multitargeted receptor tyrosine kinase inhibitor, which inhibits Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 with IC50 values of 150 nM and 90 nM, respectively.
    Quick View
  11. A10248
    CYC116

    Aurora Kinase inhibitor

    Aurora kinase/VEGFR 2 inhibitor CYC116 inhibits Aurora kinases A and B and vascular endothelial growth factor receptor 2 (VEGFR2), resulting in disruption of the cell cycle, rapid cell death, and the inhibition of angiogenesis.
    Quick View
  12. A10250
    Regorafenib (BAY 73-4506)

    VEGFR inhibitor

    Regorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an orally bioavailable multikinase inhibitor targeting both the tumor and its vasculature.
    Quick View
  13. A10254
    Brivanib (BMS-540215)

    VEGFR-2 inhibitor

    Brivanib (BMS-540215) is a VEGFR -2 inhibitor with an IC50 of 25 nM and Ki of 26 nM.
    Quick View
  14. A10340
    E7080 (Lenvatinib)

    VEGFR Inhibitor

    E7080 is a multi-kinase inhibitor that inhibits both VEGFR2 and VEGFR3 kinases.
    Quick View
  15. A10352
    ENMD-2076

    Aurora A / FLT3 Inhibitor

    ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα. Phase 2.
    Quick View
  16. A10502
    Ki8751

    VEGFR-2 inhibitor

    Ki8751 is a cell-permeable quinolyloxyphenyl-urea compound that acts as a Flk-1 (VEGFR-2)-selective inhibitior in both cell-based and cell-free assays.
    Quick View
  17. A10504
    KRN 633

    VEGFR Inhibitor

    KRN 633 is a cell-permeable, reversible, ATP-competitive VEGFR kinase inhibitor that inhibits PDGFR-α and c-Kit at higher concentrations only (IC50 = 0.97 μM and 4.33 μM, respectively) and inactive towards 17 other kinases (IC50 ??? 10 μM).
    Quick View
  18. A10587
    MGCD-265 (Glesatinib)

    c-Met inhibitor

    MGCD265 is a multitargeted tyrosine kinase inhibitor that binds to and inhibits the phosphorylation of several RTKs, including the c-Met receptor (HGFR); the Tek/Tie-2 receptor; VEGFR types 1, 2, and 3; and MST1R.
    Quick View
  19. A10608
    Motesanib Diphosphate (AMG-706)

    VEGFR inhibitor

    Motesanib, also known as AMG-706, is an orally administered multikinase inhibitor that selectively targets VEGF receptors, platelet-derived growth factor receptors, and Kit receptors.
    Quick View
  20. A10679
    OSI-930

    c-Kit/VEGFR Inhibitor

    OSI-930 is a potent inhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck with IC50 of 80 nM, 9 nM, 8 nM, 15 nM, 41 nM and 22 nM, respectively.
    Quick View
  21. A10699
    Pazopanib HCl (GW786034)

    VEGFR/PDGFR/FGFR inhibitor

    Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis.
    Quick View
  22. A10703
    PD173074

    FGFR1/VEGFR2 Inhibitor

    PD173074 is a potent, cell permeable and ATP competitive inhibitor of FGFR and VEGFR.
    Quick View
  23. A10773
    RAF265 (CHIR-265)

    RAF/VEGFR Inhibitor

    RAF265 (CHIR-265) is an oral, highly selective RAF and VEGFR kinase inhibitor, which is to control or normalize VEGFR-2 along with the inhibition of B-raf and c-Raf mutation to prevent cancers.
    Quick View
  24. A10774
    Raf265 derivative

    RAF/VEGFR Inhibitor

    Raf265 derivative is a derivative of Raf265 that is an oral, highly selective RAF and VEGFR kinase inhibitor with IC50 of of 5 to 10 μM.
    Quick View
  25. A10880
    Sunitinib Malate

    RTK inhibitor

    Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).
    Quick View
  26. A10893
    Taxifolin

    VEGFR-2 Inhibitor

    Taxifolin is found to bind at the ATP-binding site on VEGFR-2 kinase with large value of binding energy and act as type I competitive inhibitor.
    Quick View
  27. A10903
    Telatinib (BAY 57-9352)

    VEGFR-2 inhibitor

    Telatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor receptor β tyrosine kinases.
    Quick View
  28. A10963
    Vandetanib (ZD6474)

    VEGFR inhibitor

    Vandetanib (Zactima) is a VEGFR and EGFR antagonist and a tyrosine kinase inhibitor with IC50 of 60, 90, 40 nM for HUVEC proliferation, PC-9 cells and tyrosine kinase activity, respectively.
    Quick View
  29. A10967
    Vatalanib (PTK787) 2HCl

    VEGFR inhibitor

    Vatalanib (PTK787 or PTK/ZK) is a small molecule protein kinase inhibitor that inhibits angiogenesis that inhibits all known VEGF receptors, as well as platelet-derived growth factor receptor-beta and c-kit, but is most selective for VEGFR-2. CAS: 212141-51-0 (HCl) 212141-54-3 (Free base)
    Quick View
  30. A10996
    XL184 free base (Cabozantinib)

    VEGFR inhibitor

    XL184 free base (Cabozantinib) is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2.
    Quick View
  31. A10998
    Foretinib (GSK1363089, XL880)

    c-MET inhibitor

    Foretinib (GSK1363089), a multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces Anoikis, and impairs ovarian cancer metastasis.
    Quick View
  32. A11057
    XL647 (Tesevatinib)

    EGFR, HER2 and VEGFR inhibitor

    XL647 is an orally bioavailable small-molecule RTK inhibitor that binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including EGFR, HER2, ERBB2, VEGFR and EphB4.
    Quick View
  33. A11207
    PP121

    PI3K Inhibitor

    PP121 is a dual inhibitor of receptor tyrosine kinases (RTKs) (IC50 < 0.02 μM for Abl, Src, VEGFR-2 and PDGFR) and PI 3-K family kinases (IC50 < 0.06 μM for p110α, DNA-PK and mTOR).
    Quick View
  34. A11244
    LY 2874455

    FGFR/VEGFR2 inhibitor

    LY2874455 is a novel and potent FGFR/VEGFR Inhibitor.
    Quick View
  35. A11263
    BMS-690514

    VEGFR/EGFR Inhibitor

    BMS-690514 is a potent and selective inhibitor of epidermal growth factor receptor (EGFR), HER2, and HER4, as well as the VEGF receptor kinases.
    Quick View
  36. A11349
    Cabozantinib S-malate

    multiple receptor tyrosine kinases inhibitor

    Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
    Quick View
  37. A11396
    E-7050 (Golvatinib)

    c-Met/VEGFR-2 inhibitor

    E7050 (also known as golvatinib is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity.
    Quick View
  38. A11407
    Apatinib (YN968D1)

    VEGFR inhibitor

    Apatinib (YN968D1) is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR) that inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue.
    Quick View
  39. A11411
    Dovitinib (TKI-258)

    RTK inhibitor

    Dovitinib is a small-molecule multitargeted receptor tyrosine kinase inhibitor, which inhibits Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 with IC50 values of 150 nM and 90 nM, respectively.
    Quick View
  40. A11472
    Ki 20227

    M-CSFR, CSF1R inhibitor

    Ki 20227 is an inhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R).
    Quick View
  41. A11496
    Motesanib (AMG706)

    VEGFR Inhibitor

    Motesanib (AMG706) is a multikinase inhibitor that selectively targets VEGF receptors, platelet-derived growth factor receptors (PDGFRs), and Kit receptors with IC?? values of 2 nM (VEGFR1), 3 nM (VEGFR2), 6 nM (VEGFR3), 84 nM (PDGFR), and 8 nM (Kit).
    Quick View
  42. A11518
    Pazopanib (GW-786034)

    VEGFR inhibitor

    Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis.
    Quick View
  43. A11546
    Regorafenib Hydrochloride

    VEGFR1/2/3/PDGFRβ/Kit/RET/Raf-1 inhibitor

    Regorafenib Hydrochloride is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.
    Quick View
  44. A11556
    SU14813 maleate

    multi-targeted receptor tyrosine kinases inhibitor

    SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.
    Quick View
  45. A11557
    SU14813

    VEGFR Inhibitor

    SU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), KIT, and fms-like tyrosine kinase 3 (FLT-3)
    Quick View
  46. A11558
    SU-5402

    VEGFR/FGFR/EGFR inhibitor?€?

    SU-5402 is a potent and selective vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) inhibitor (IC50 values are 0.02, 0.03, 0.51 and > 100 μM at VEGFR2, FGFR1, PDGFRβ and EGFR respectively).
    Quick View
  47. A11581
    Toceranib (PHA 291639, SU 11654)

    c-Kit, PDGFR, VEGFR inhibitor

    Toceranib is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ.
    Quick View
  48. A11737
    Buflomedil HCl

    VEGFR Antagonist

    Buflomedil is a vasoactive agent used to treat peripheral vascular disease.
    Quick View
  49. A11772
    CP-547632

    VEGFR2 inhibitor

    CP-547632 is a novel, potent vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor
    Quick View
  50. A11954
    ZM 323881 hydrochloride

    VEGFR Inhibitor

    ZM 323881 is a potent and selective inhibitor of the kinase activity of the human vascular endothelial growth factor receptor 2 (VEGFR2/KDR).
    Quick View

Items 1-50 of 124

Page
per page
Set Descending Direction